221 related articles for article (PubMed ID: 20180072)
21. Papillary thyroid cancer.
Caron NR; Clark OH
Curr Treat Options Oncol; 2006 Jul; 7(4):309-19. PubMed ID: 16916491
[TBL] [Abstract][Full Text] [Related]
22. [Current practice in treatment of differentiated thyroid cancer in Japan in comparison with the guidelines in Western countries].
Miyauchi A
Nihon Rinsho; 2007 Nov; 65(11):2023-8. PubMed ID: 18018565
[TBL] [Abstract][Full Text] [Related]
23. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy.
Ito Y; Masuoka H; Fukushima M; Inoue H; Kihara M; Tomoda C; Higashiyama T; Takamura Y; Kobayashi K; Miya A; Miyauchi A
World J Surg; 2010 Jun; 34(6):1285-90. PubMed ID: 20041244
[TBL] [Abstract][Full Text] [Related]
24. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
25. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
26. Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma.
Sakai T; Sugitani I; Ebina A; Fukuoka O; Toda K; Mitani H; Yamada K
Thyroid; 2019 Jan; 29(1):59-63. PubMed ID: 30560718
[TBL] [Abstract][Full Text] [Related]
27. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
28. Papillary thyroid cancer.
Sosa JA; Udelsman R
Surg Oncol Clin N Am; 2006 Jul; 15(3):585-601. PubMed ID: 16882499
[TBL] [Abstract][Full Text] [Related]
29. Unique treatment policy for well-differentiated thyroid cancer in Japan: results of a questionnaire distributed to members of the Japanese Society of Thyroid Surgery and the International Association of Endocrine Surgeons.
Shigematsu N; Takami H; Kubo A
Endocr J; 2006 Dec; 53(6):829-39. PubMed ID: 17001109
[TBL] [Abstract][Full Text] [Related]
30. Changing management in patients with papillary thyroid cancer.
Elaraj DM; Clark OH
Curr Treat Options Oncol; 2007 Aug; 8(4):305-13. PubMed ID: 18040607
[TBL] [Abstract][Full Text] [Related]
31. [Unique treatment policy for thyoid cancer in Japan and other countries].
Takami H
Nihon Geka Gakkai Zasshi; 2008 Nov; 109(6):355-6. PubMed ID: 19068718
[TBL] [Abstract][Full Text] [Related]
32. Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence.
Palmer BA; Zarroug AE; Poley RN; Kollars JP; Moir CR
J Pediatr Surg; 2005 Aug; 40(8):1284-8. PubMed ID: 16080933
[TBL] [Abstract][Full Text] [Related]
33. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
34. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center.
Dobrinja C; Troian M; Cipolat Mis T; Rebez G; Bernardi S; Fabris B; Piscopello L; Makovac P; Di Gregorio F; de Manzini N
Int J Surg; 2017 May; 41 Suppl 1():S40-S47. PubMed ID: 28506412
[TBL] [Abstract][Full Text] [Related]
35. Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery.
Oda H; Miyauchi A; Ito Y; Yoshioka K; Nakayama A; Sasai H; Masuoka H; Yabuta T; Fukushima M; Higashiyama T; Kihara M; Kobayashi K; Miya A
Thyroid; 2016 Jan; 26(1):150-5. PubMed ID: 26426735
[TBL] [Abstract][Full Text] [Related]
36. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
37. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
38. Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid?
Monchik JM; Simon CJ; Caragacianu DL; Thomay AA; Tsai V; Cohen J; Mazzaglia PJ
Surgery; 2009 Dec; 146(6):1182-7. PubMed ID: 19958947
[TBL] [Abstract][Full Text] [Related]
39. Insights into the Management of Papillary Microcarcinoma of the Thyroid.
Miyauchi A; Ito Y; Oda H
Thyroid; 2018 Jan; 28(1):23-31. PubMed ID: 28629253
[TBL] [Abstract][Full Text] [Related]
40. Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance.
Lin JF; Jonker PKC; Cunich M; Sidhu SB; Delbridge LW; Glover AR; Learoyd DL; Aniss A; Kruijff S; Sywak MS
Surgery; 2020 Jan; 167(1):110-116. PubMed ID: 31543327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
